Published in J Gastroenterol on July 01, 2005
Differential, type I interferon-mediated autophagic trafficking of hepatitis C virus proteins in mouse liver. Gastroenterology (2011) 1.52
Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. J Gastroenterol (2009) 0.88
NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation. Br J Cancer (2010) 0.86
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80
The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res (2003) 3.58
Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology (2000) 3.42
Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. Science (1995) 3.10
Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology (1998) 2.62
Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem (2001) 2.07
Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem (2001) 1.71
Development of anticancer drugs targeting the MAP kinase pathway. Oncogene (2000) 1.63
Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood (2001) 1.54
Interferon alpha /beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem (2001) 1.53
Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet (2001) 1.52
Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology (2002) 1.48
Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene (2003) 1.31
Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer (2003) 1.25
Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ (1997) 1.23
Interferons in the treatment of human cancer. J Clin Oncol (1984) 1.22
Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem (2002) 1.21
Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett (2003) 1.18
Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ (2002) 1.15
Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood (2002) 1.13
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology (2000) 1.10
Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology (1999) 1.08
Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology (1993) 0.99
Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats. Gastroenterology (2003) 0.97
Alpha-interferon and its effects on signalling pathways within cells. Curr Protein Pept Sci (2004) 0.97
Retinoic acid enhances the expression of interferon-induced proteins: evidence for multiple mechanisms of action. Oncogene (1997) 0.97
High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2. J Biol Chem (2001) 0.94
Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem (2001) 0.93
Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res (2001) 0.93
Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol (2004) 0.91
Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology (2002) 0.90
Interferon beta promotes survival in primary astrocytes through phosphatidylinositol 3-kinase. J Neuroimmunol (2003) 0.89
Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology (2001) 0.88
The role of collagen structure in mitogen stimulation of ERK, cyclin D1 expression, and G1-S progression in rat hepatocytes. J Biol Chem (2003) 0.88
Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res (2002) 0.87
Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. Cancer Res (1991) 0.86
Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw (1998) 0.85
Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice. Oncogene (2003) 0.84
Dissociation between IFN-alpha-induced anti-viral and growth signaling pathways. J Immunol (1999) 0.83
Interferon-alpha inhibits cell cycle progression by Ba/F3 cells through the antagonisation of interleukin-3 effects on key regulators of G(1)/S transition. Cell Signal (2002) 0.79
Increased serine phosphorylation and activation of STAT1 by oncogenic Ras transfection. Mol Cells (2002) 0.79
Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene. Oncogene (2002) 0.79
Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha. Br J Cancer (1999) 0.76
The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves Bax protein. Hepatology (2002) 0.75
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology (2007) 2.24
Preventive and therapeutic effects of angiotensin II type 1 receptor blocker on hepatic fibrosis induced by bile duct ligation in rats. J Gastroenterol (2006) 1.53
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology (2006) 1.43
Myocardial injury in patients with chronic hepatitis C infection. J Hepatol (2012) 1.18
Hepatocyte growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway. Biochem Biophys Res Commun (2003) 1.17
Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology (2004) 1.16
Percutaneous sonographically guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma located under the diaphragm. AJR Am J Roentgenol (2004) 1.13
A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol (2010) 1.10
Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma. Hepatol Res (2003) 1.09
Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med (2009) 1.06
Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett (2007) 1.05
The impact of visceral fat in nonalcoholic fatty liver disease: cross-sectional and longitudinal studies. J Gastroenterol (2007) 1.02
Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients. Hepatol Res (2012) 1.02
Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res (2005) 1.01
miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One (2013) 1.00
Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2'-deoxyguanosine formation. Hepatology (2002) 0.99
Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol (2009) 0.98
Effect of pancreatic juice cytology and/or endoscopic ultrasound-guided fine-needle aspiration biopsy for pancreatic tumor. J Gastroenterol Hepatol (2014) 0.97
Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. Exp Hematol (2004) 0.96
Diaphragmatic perforation and hernia after hepatic radiofrequency ablation. AJR Am J Roentgenol (2003) 0.95
Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin Pharmacol Toxicol (2008) 0.95
Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J Gastroenterol Hepatol (2005) 0.94
No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. BMC Med Genet (2012) 0.94
Right diaphragmatic defect in hepatic hydrothorax exposed by contrast-enhanced ultrasonography after radiofrequency ablation. Hepatology (2012) 0.93
Expression of 8-hydroxy-2'-deoxyguanosine in chronic liver disease and hepatocellular carcinoma. Liver Int (2003) 0.91
The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med (2010) 0.90
Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol (2011) 0.90
The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol Res (2004) 0.90
Contrast-enhanced sonography with perflubutane revealing active bleeding as a complication of radiofrequency ablation. Hepatology (2012) 0.89
Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition. Int J Oncol (2006) 0.89
Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma. Cancer Lett (2003) 0.88
Reduction of hepatocarcinogenesis by ursodeoxycholic acid in rats. Carcinogenesis (2002) 0.88
Sonographic subcutaneous and visceral fat indices represent the distribution of body fat volume. Abdom Imaging (2006) 0.88
Hepatitis B and C virus infection is a risk factor for the development of cholangiocarcinoma. Intern Med (2012) 0.87
Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells. J Gastroenterol (2006) 0.87
Rapid identification of bacterial species with bacterial DNA microarray in cirrhotic patients with spontaneous bacterial peritonitis. Intern Med (2009) 0.86
The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep (2008) 0.86
Primary effusion lymphoma of the left scrotum. Intern Med (2003) 0.86
Prevalence of organic colonic lesions in patients meeting Rome III criteria for diagnosis of IBS: a prospective multi-center study utilizing colonoscopy. J Gastroenterol (2012) 0.86
Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on non-alcoholic steatohepatitis using FLS-ob/ob male mice. Int J Mol Med (2012) 0.86
Qualitative assessment of tumor vascularity in hepatocellular carcinoma by contrast-enhanced coded ultrasound: comparison with arterial phase of dynamic CT and conventional color/power Doppler ultrasound. Eur Radiol (2003) 0.86
Expression of transforming growth factor-beta 1 in hepatocellular carcinoma in comparison with the non-tumor tissue. Hepatogastroenterology (2003) 0.85
Analyses to clarify rich fractions in hepatic progenitor cells from human umbilical cord blood and cell fusion. Biochem Biophys Res Commun (2004) 0.85
Isolated metastases of hepatocellular carcinoma in the right atrium: Case report and review of the literature. Oncol Lett (2013) 0.85
Schistosomiasis japonica identified by laparoscopic and colonoscopic examination. Dig Endosc (2010) 0.84
Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice. Hepatol Res (2013) 0.83
Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue. Res Commun Mol Pathol Pharmacol (2004) 0.83
Fhit, Mlh1, P53 and phenotypic expression in the early stage of colorectal neoplasms. Oncol Rep (2008) 0.83
A noncoding RNA gene on chromosome 10p15.3 may function upstream of hTERT. BMC Mol Biol (2009) 0.83
Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice. Hepatol Res (2011) 0.83
The growth inhibition of liver cancer cells by paclitaxel and the involvement of extracellular signal-regulated kinase and apoptosis. Oncol Rep (2007) 0.82
Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res (2006) 0.81
Picosecond IR-UV pump-probe spectroscopic study on the intramolecular vibrational energy redistribution of NH2 and CH stretching vibrations of jet-cooled aniline. J Chem Phys (2005) 0.81
Regulation of hepatic oval cell proliferation by adenoviral mediated hepatocyte growth factor gene transfer and signal transduction inhibitors. Hepatogastroenterology (2007) 0.80
[Case report; Acute renal failure due to IgG4-related retroperitoneal fibrosis]. Nihon Naika Gakkai Zasshi (2012) 0.80
Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study. Hepatol Res (2012) 0.80
Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression. J Gastroenterol (2013) 0.80
The association of MMP-1, -3 and -9 genotypes with the prognosis of HCV-related hepatocellular carcinoma patients. Res Commun Mol Pathol Pharmacol (2005) 0.80
Fhit, E-cadherin, p53, and activation-induced cytidine deaminase expression in endoscopically resected early stage esophageal squamous neoplasia. J Gastroenterol Hepatol (2012) 0.80
Clinicopathological and patient characteristics of early gastric neoplasia endoscopically resected with loss of Mlh1 expression. Oncol Lett (2010) 0.80
Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Hepatogastroenterology (2009) 0.79
Fatty liver Shionogi-ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis model. Hepatol Res (2012) 0.79
Assessment of the ablated area after radiofrequency ablation by contrast-enhanced sonography; comparison with virtual sonography with magnetic navigation. Clin Imaging (2010) 0.79
Protection by Exogenously Added Coenzyme Q(9) against Free Radical-Induced Injuries in Human Liver Cells. J Clin Biochem Nutr (2010) 0.79
Cerebral pulsatility index by transcranial Doppler sonography predicts the prognosis of patients with fulminant hepatic failure. Clin Imaging (2010) 0.79
The effects of the selective mineralocorticoid receptor antagonist eplerenone on hepatic fibrosis induced by bile duct ligation in rat. Int J Mol Med (2010) 0.79
Effect of promoter methylation of the p16 gene on phosphorylation of retinoblastoma gene product and growth of hepatocellular carcinoma cells. Tumour Biol (2005) 0.78
Naked gene therapy of hepatocyte growth factor for dextran sulfate sodium-induced colitis in mice. Biochem Biophys Res Commun (2006) 0.78
Usefulness of contrast-enhanced ultrasound with Sonazoid for evaluating liver abscess in comparison with conventional B-mode ultrasound. Hepatol Res (2014) 0.78
Therapeutic effect of adenoviral-mediated hepatocyte growth factor gene administration on TNBS-induced colitis in mice. Biochem Biophys Res Commun (2005) 0.78
Preventive effect of caffeine and curcumin on hepato-carcinogenesis in diethylnitrosamine-induced rats. Int J Oncol (2012) 0.78
The therapeutic potential of RNA interference: novel approaches for cancer treatment. Curr Pharm Biotechnol (2012) 0.78
[Evaluation of the surveillance program for hepatocellular carcinoma]. Nihon Shokakibyo Gakkai Zasshi (2012) 0.78
Expression of AID, P53, and Mlh1 proteins in endoscopically resected differentiated-type early gastric cancer. World J Gastrointest Oncol (2012) 0.78
Sequential analysis of diethylnitrosamine-induced hepatocarcinogenesis in rats. Exp Ther Med (2011) 0.78
Endothelin-1 enhances fibrogenic gene expression, but does not promote DNA synthesis or apoptosis in hepatic stellate cells. Comp Hepatol (2006) 0.78
Assessment of the ablated area after radiofrequency ablation by the spread of bubbles: comparison with virtual sonography with magnetic navigation. Hepatogastroenterology (2011) 0.78
Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells. Oncol Rep (2007) 0.77
Preventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on DEN-induced hepatocarcinogenesis in rats. Biomed Pharmacother (2010) 0.77
Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition. Eur J Radiol (2011) 0.77
Comparison between different thickness umbrella-shaped expandable radiofrequency electrodes (SuperSlim and CoAccess): Experimental and clinical study. Exp Ther Med (2011) 0.76
Extracellular matrix metabolism-related gene expression in bile duct-ligated rats. Mol Med Rep (2011) 0.76
Preventive effects of ME3738 on hepatic fibrosis induced by bile duct ligation in rats. Hepatol Res (2008) 0.76
Preventative and therapeutic effects of perindopril on hepatic fibrosis induced by bile duct ligation in rats. Mol Med Rep (2011) 0.76
Expression of oxidative stress-related molecules in circulating leukocytes and urine in patients with chronic viral hepatitis. Liver Int (2006) 0.75
Association between gene polymorphisms of connective tissue growth factor and the progression of chronic liver disease associated with hepatitis C. Intern Med (2014) 0.75
The Effects of Olmesartan and Alfacalcidol on Renoprotection and klotho Gene Expression in 5/6 Nephrectomized Spontaneously Hypertensive Rats. Yonago Acta Med (2011) 0.75
The prevalence of atherosclerosis in cirrhotic patients: assessment of two aspects of atherosis and sclerosis. Hepatol Res (2007) 0.75
[Case of villous tumor of the rectum presenting with severe diarrhea and electrolyte depletion syndrome]. Nihon Shokakibyo Gakkai Zasshi (2009) 0.75
Functional gene polymorphisms of interleukin-10 are associated with liver disease progression in Japanese patients with hepatitis C virus infection. Intern Med (2011) 0.75
Expression of Fhit, Mlh1, p16INK4A and E-cadherin in early gastric neoplasia: Correlation with histological grade and gastric phenotype. Oncol Rep (2007) 0.75
Cowden syndrome complicated with hepatocellular carcinoma possibly originating from non-alcoholic steatohepatitis (NASH). Hepatol Res (2011) 0.75
[Community health and medicine for gastrointestinal disease]. Nihon Shokakibyo Gakkai Zasshi (2010) 0.75
[Two cases of primary T cell lymphoma of the small intestine diagnosed by perforated peritonitis]. Nihon Shokakibyo Gakkai Zasshi (2007) 0.75
[Q & A: differential diagnosis of epigastric pain and chronic watery diarrhea]. Nihon Shokakibyo Gakkai Zasshi (2010) 0.75
Hepatocellular carcinoma with sarcomatous change arising after eradication of HCV via interferon therapy. Clin Imaging (2006) 0.75